Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.1K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.1K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining Haplosufficiency in Autosomal Recessive Limb-Girdle Muscular Dystrophy Using Molecular Markers in Disease Carriers.

Neurology. Genetics·2026
Same author

Education Research: The Future of Child Neurology Residency Training: The Perspective of a Child Neurology Society Task Force.

Neurology. Education·2026
Same author

Five-Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a Study.

Muscle & nerve·2026
Same author

Changes in Provision of Recommended Cardiac Care for Duchenne Muscular Dystrophy Using a Longitudinal Cohort.

Muscle & nerve·2026
Same author

Longitudinal Psychometric Properties of the Myotonic Dystrophy Health Index in a Large Multicenter Cohort of People Living With Myotonic Dystrophy Type 1.

Muscle & nerve·2026
Same author

Updating <i>Neurology</i>® Journals' Policies on AI Use, Reporting of Genetic Studies, and Protocols for Systematic Review.

Neurology·2026

Related Experiment Video

Updated: Sep 13, 2025

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

53.9K

Limb-Girdle Muscular Dystrophy Scientific Workshop: A Multistakeholder Discussion Focused on Charting the Path

Matthew P Wicklund1, Lindsay N Alfano2, Nicholas E Johnson3

  • 1Department of Neurology, UT Health San Antonio.

Neurology. Clinical Practice
|August 4, 2025
PubMed
Summary

Limb-girdle muscular dystrophy (LGMD) drug development faces challenges due to disease complexity. A workshop convened experts to explore strategies for advancing new LGMD therapies and treatments.

More Related Videos

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies
14:10

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

Published on: January 31, 2013

33.2K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

6.9K

Related Experiment Videos

Last Updated: Sep 13, 2025

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

53.9K
Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies
14:10

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

Published on: January 31, 2013

33.2K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

6.9K

Area of Science:

  • Neurology
  • Genetics
  • Drug Development

Background:

  • Limb-girdle muscular dystrophy (LGMD) causes progressive muscle weakness, disability, and premature death.
  • Disease heterogeneity and variable progression complicate traditional drug development for LGMD.

Purpose of the Study:

  • To discuss challenges and opportunities in advancing drug development for LGMD.
  • To foster collaboration among stakeholders for LGMD therapy development.

Main Methods:

  • A multistakeholder workshop was convened on February 8, 2024.
  • Participants included academic experts, patients, advocacy groups, FDA leaders, and drug developers.

Main Results:

  • Discussions covered LGMD pathophysiology, natural history, and clinical outcomes.
  • Key topics included patient-focused drug development, surrogate endpoints, and Accelerated Approval.

Conclusions:

  • Addressing LGMD drug development requires a comprehensive, collaborative approach.
  • Future directions focus on innovative strategies to overcome therapeutic hurdles.